315 related articles for article (PubMed ID: 33705824)
1. The genetic background significantly impacts the severity of kidney cystic disease in the Pkd1
Arroyo J; Escobar-Zarate D; Wells HH; Constans MM; Thao K; Smith JM; Sieben CJ; Martell MR; Kline TL; Irazabal MV; Torres VE; Hopp K; Harris PC
Kidney Int; 2021 Jun; 99(6):1392-1407. PubMed ID: 33705824
[TBL] [Abstract][Full Text] [Related]
2. Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model.
Pastor-Soler NM; Li H; Pham J; Rivera D; Ho PY; Mancino V; Saitta B; Hallows KR
Am J Physiol Renal Physiol; 2022 Jan; 322(1):F27-F41. PubMed ID: 34806449
[TBL] [Abstract][Full Text] [Related]
3. Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model.
Hopp K; Hommerding CJ; Wang X; Ye H; Harris PC; Torres VE
J Am Soc Nephrol; 2015 Jan; 26(1):39-47. PubMed ID: 24994926
[TBL] [Abstract][Full Text] [Related]
4. A study of sirolimus and mTOR kinase inhibitor in a hypomorphic
Holditch SJ; Brown CN; Atwood DJ; Lombardi AM; Nguyen KN; Toll HW; Hopp K; Edelstein CL
Am J Physiol Renal Physiol; 2019 Jul; 317(1):F187-F196. PubMed ID: 31042058
[TBL] [Abstract][Full Text] [Related]
5. Metabolic reprogramming in a slowly developing orthologous model of polycystic kidney disease.
Hopp K; Kleczko EK; Gitomer BY; Chonchol M; Klawitter J; Christians U; Klawitter J
Am J Physiol Renal Physiol; 2022 Mar; 322(3):F258-F267. PubMed ID: 35037466
[TBL] [Abstract][Full Text] [Related]
6. Scattered Deletion of PKD1 in Kidneys Causes a Cystic Snowball Effect and Recapitulates Polycystic Kidney Disease.
Leonhard WN; Zandbergen M; Veraar K; van den Berg S; van der Weerd L; Breuning M; de Heer E; Peters DJ
J Am Soc Nephrol; 2015 Jun; 26(6):1322-33. PubMed ID: 25361818
[TBL] [Abstract][Full Text] [Related]
7. Protein Kinase A Downregulation Delays the Development and Progression of Polycystic Kidney Disease.
Wang X; Jiang L; Thao K; Sussman CR; LaBranche T; Palmer M; Harris PC; McKnight GS; Hoeflich KP; Schalm S; Torres VE
J Am Soc Nephrol; 2022 Jun; 33(6):1087-1104. PubMed ID: 35236775
[TBL] [Abstract][Full Text] [Related]
8. Autosomal dominant polycystic kidney disease in a family with mosaicism and hypomorphic allele.
Reiterová J; Štekrová J; Merta M; Kotlas J; Elišáková V; Lněnička P; Korabečná M; Kohoutová M; Tesař V
BMC Nephrol; 2013 Mar; 14():59. PubMed ID: 23496908
[TBL] [Abstract][Full Text] [Related]
9. Patients with Protein-Truncating
Lanktree MB; Guiard E; Akbari P; Pourafkari M; Iliuta IA; Ahmed S; Haghighi A; He N; Song X; Paterson AD; Khalili K; Pei YPC
Clin J Am Soc Nephrol; 2021 Mar; 16(3):374-383. PubMed ID: 33602752
[TBL] [Abstract][Full Text] [Related]
10. Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity.
Hopp K; Ward CJ; Hommerding CJ; Nasr SH; Tuan HF; Gainullin VG; Rossetti S; Torres VE; Harris PC
J Clin Invest; 2012 Nov; 122(11):4257-73. PubMed ID: 23064367
[TBL] [Abstract][Full Text] [Related]
11. Triptolide reduces cyst formation in a neonatal to adult transition Pkd1 model of ADPKD.
Leuenroth SJ; Bencivenga N; Chahboune H; Hyder F; Crews CM
Nephrol Dial Transplant; 2010 Jul; 25(7):2187-94. PubMed ID: 20139063
[TBL] [Abstract][Full Text] [Related]
12. Ouabain enhances renal cyst growth in a slowly progressive mouse model of autosomal dominant polycystic kidney disease.
Trant J; Sanchez G; McDermott JP; Blanco G
Am J Physiol Renal Physiol; 2023 Dec; 325(6):F857-F869. PubMed ID: 37823195
[TBL] [Abstract][Full Text] [Related]
13. Modifiers of Autosomal Dominant Polycystic Kidney Disease Severity: The Role of
Ambrosini E; Montanari F; Cristalli CP; Capelli I; La Scola C; Pasini A; Graziano C
Genes (Basel); 2023 Jun; 14(6):. PubMed ID: 37372410
[TBL] [Abstract][Full Text] [Related]
14. CD8
Kleczko EK; Marsh KH; Tyler LC; Furgeson SB; Bullock BL; Altmann CJ; Miyazaki M; Gitomer BY; Harris PC; Weiser-Evans MCM; Chonchol MB; Clambey ET; Nemenoff RA; Hopp K
Kidney Int; 2018 Dec; 94(6):1127-1140. PubMed ID: 30249452
[TBL] [Abstract][Full Text] [Related]
15. Identification of pathological transcription in autosomal dominant polycystic kidney disease epithelia.
Friedrich S; Müller H; Riesterer C; Schüller H; Friedrich K; Wörner CL; Busch T; Viau A; Kuehn EW; Köttgen M; Hofherr A
Sci Rep; 2021 Jul; 11(1):15139. PubMed ID: 34301992
[TBL] [Abstract][Full Text] [Related]
16. Growth Pattern of Kidney Cyst Number and Volume in Autosomal Dominant Polycystic Kidney Disease.
Bae KT; Zhou W; Shen C; Landsittel DP; Wu Z; Tao C; Chapman AB; Torres VE; Yu ASL; Mrug M; Bennett WM; Harris PC;
Clin J Am Soc Nephrol; 2019 Jun; 14(6):823-833. PubMed ID: 31088850
[TBL] [Abstract][Full Text] [Related]
17. Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease.
Heyer CM; Sundsbak JL; Abebe KZ; Chapman AB; Torres VE; Grantham JJ; Bae KT; Schrier RW; Perrone RD; Braun WE; Steinman TI; Mrug M; Yu AS; Brosnahan G; Hopp K; Irazabal MV; Bennett WM; Flessner MF; Moore CG; Landsittel D; Harris PC;
J Am Soc Nephrol; 2016 Sep; 27(9):2872-84. PubMed ID: 26823553
[TBL] [Abstract][Full Text] [Related]
18. Probenecid slows disease progression in a murine model of autosomal dominant polycystic kidney disease.
Arkhipov SN; Potter DL; Sultanova RF; Ilatovskaya DV; Harris PC; Pavlov TS
Physiol Rep; 2023 Apr; 11(7):e15652. PubMed ID: 37024297
[TBL] [Abstract][Full Text] [Related]
19. The effect of trehalose on autophagy-related proteins and cyst growth in a hypomorphic Pkd1 mouse model of autosomal dominant polycystic kidney disease.
Atwood DJ; Brown CN; Holditch SJ; Pokhrel D; Thorburn A; Hopp K; Edelstein CL
Cell Signal; 2020 Nov; 75():109760. PubMed ID: 32866627
[TBL] [Abstract][Full Text] [Related]
20. Current advances in molecular genetics of autosomal-dominant polycystic kidney disease.
Wu G
Curr Opin Nephrol Hypertens; 2001 Jan; 10(1):23-31. PubMed ID: 11195048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
